Monoclonal antibody therapy for central nervous system lymphomas: An emerging treatment paradigm

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 7, 2005, Pages 1107-1114

  Wong, Eric T ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Brain; Lymphoma; Monoclonal antibody

Indexed keywords

ALEMTUZUMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; HYDROCORTISONE; IBRITUMOMAB TIUXETAN; METHOTREXATE; METHYLPREDNISOLONE; NATALIZUMAB; PREDNISONE; RITUXIMAB; TEMOZOLOMIDE; TOSITUMOMAB I 131; VINCRISTINE;

ANTIBODY ENGINEERING; ASTHENIA; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CHILL; CLINICAL TRIAL; COMPLEMENTARITY DETERMINING REGION; DEMENTIA; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG PENETRATION; FEVER; GAIT DISORDER; HUMAN; HYPOTENSION; INFUSION REACTION; LEUKOENCEPHALOPATHY; LEUKOPENIA; LIVER DYSFUNCTION; MEDICAL TECHNOLOGY; MOLECULAR CLONING; MOUSE; MUCOSA INFLAMMATION; NAUSEA; NEUROIMAGING; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHAGE DISPLAY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RIGOR; THROMBOCYTOPENIA; URINE INCONTINENCE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, CD20; ANTIGENS, CD22; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIALS; GENETIC ENGINEERING; GLYCOPROTEINS; HUMANS; LYMPHOMA; PEPTIDE LIBRARY;

EID: 21844454717     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.7.1107     Document Type: Review

References (62)

1. DEANGELIS LM, YAHALOM J, THALER HT et al.: Combined modality therapy for primary CNS lymphoma. J. Clin. Oncol. (1992) 10:635-643.
2. MCLAUGHLIN P, VELASQUEZ WS, REDMAN JR et al.: Chemotherapy with dexamethasone, high-dose cytarabine, and cisplacin for parenchymal brain lymphoma. J. Natl. Cancer Inst. (1988) 80:1408-1412.
3. HERRLINGER U, BRUGGER W, BAMBERG M et al.: PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology (2000) 54:1707-1708.
4. CIORDIA R, HOCHBERG FH, BATCHELOR TT: Topotecan as salvage therapy for refractory or relapsed primary central nervous system lymphoma. Proc. Am. Soc. Clin. Oncol. (2000) 19:165a.
5. WONG ET: Correspondence: immunochemotherapy with rituximab and temozolomide for central nervous system lymphoma. Cancer (2004) 101:2900-2902.
6. DIGIUSEPPE JA, NELSON WG, SEIFTER EJ, BOITNOTT JK, MANN RB: Intravascular lymphomatosis: a clinicopathologic study of 10 cases and assessment of response to chemotherapy. J. Clin. Oncol. (1994) 12:2573-2579.
7. DEBIAIS S, BONNAUD I, COTTIER JP et al.: A spinal cord intravascular lymphomatosis with exceptionally good outcome. Neurology (2004) 63:1329-1330.
8. SCOTT TF, HOGAN EL, CARTER TD, GAREN PD, BRILLMAN J: Primary intracranial meningeal lymphoma. Am. J. Med. (1990) 89:536-538.
9. LACHANCE DH, O'NEILL BP, MACDONALD DR et al.: Primary leptomeningeal lymphoma: report of 9 cases, diagnosis with immunocytochemical analysis, and review of the literature. Neurology (1991) 41:95-100.
10. MOORE KR, BLUMENTHAL DT, SMITH AG, WARD JH: Neurolymphomatosis of the lumbar plexus: high-resolution MR neurography findings. Neurology (2001) 57:740-742.
11. HOFFMAN PM, MCKELVIE P, HALL AJ, STAWELL RJ, SANTAMARIA JD: Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes. Eye (2003) 17:513-521.
12. ZALDIVAR RA, MARTIN DF, HOLDEN JT, GROSSNIKLAUS HE: Primary intraocular lymphoma: clinical, cytologic, and flow cycometric analysis. Ophthalmology (2004) 111:1762-1767.
13. 1 integrin) and CD54 (ICAM-1) adhesion molecules in intravascular lymphomatosis. Human Pathol. (2000) 31:220-226.
14. LEVITT LJ, DAWSON DM, ROSENTHAL DS, MOLONEY WC: CNS involvement in non-Hodgkin's lymphoma. Cancer (1980) 45:545-552.
15. LIANG R, CHIU E, LOKE SL: Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors. Hematol. Oncol. (1990) 8:141-145.
16. HOFFMANN C, TABRIZIAN S, WOLF E et al.: Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS (2001) 15:2119-2127.
17. PELS H, MONTESINOS-RONGEN M, SCHALLER C et al.: Clonal evolution as pathogenetic mechanism in relapse of primary CNS lymphoma. Neurology (2004) 63:167-169.
18. KÖHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256:495-497.
19. DE HAARD HJ, VAN NEER N, REURS A et al.: A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J. Biol. Chem. (1999) 274:18218-18230.
20. BACA M, PRESTA LG, O'CONNOR SJ, WELLS JA: Antibody humanization using monovalent phage display. J. Biol. Chem. (1997) 272:10678-10684.
21. GAO C, MAO S, LO CH et al.: Making artificial antibodies: a format for phage display of combinatorial heterodimeric arrays. Proc. Natl. Acad. Sci. (1999) 96:6025-6030.
22. GAO C, MAO S, KAUFMANN G et al.: A method for the generation of combinatorial antibody libraries using pIX phage display. Proc. Natl. Acad. Sci. (2002) 99:12612-12616.
23. RADER C, CHERESH DA, BARBAS CF: A phage display approach for rapid antibody humanization: designed combinacorial V gene libraries. Proc. Natl. Acad. Sci. (1998) 95:8910-8915.
24. BRÜGGEMANN M, NEUBERGER MS: Strategies for expressing human antibody repertoires in transgenic mice. Immunol. Today (1996) 17:391-397.
25. KARPAS A, DEMUCHEVA A, CZEPULKOWSKI BH: A human myeloma cell line suitable for the generation of human monoclonal antibodies. Proc. Natl. Acad. Sci. (2001) 98:1799-1804.
26. BATCHELOR T, CARSON K, O'NEILL A et al.: Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J. Clin. Oncol. (2003) 21:1044-1049.
27. DEANGELIS LM, SEIFERHELD W, SCHOLD SC, FISHER B, SCHULTZ CJ: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J. Clin. Oncol. (2002) 20:4643-4648.
28. BLAY JY, BOUHOUR D, CARRIE C et al.: The C5R Protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression. J. Clin. Oncol. (1995) 86:2922-2929.
29. GUHA-THAKURTA N, DAMEK D, POLLACK C, HOCHBERG FH: Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J. Neurooncol. (1999) 43:259-268.
30. FISHER RI, GAYNOR ER, DAHLBERG S et al.: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. (1993) 328:1002-1006.
31. VELASQUEZ WS, MCLAUGHLIN P, TUCKER S et al.: ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J. Clin. Oncol. (1994) 12:1169-1176.
32. LACHANCE DH, BRIZEL DM, GOCKERMAN JP et al.: Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology (1994) 44:1721-1727.
33. SCHULTZ C, SCOTT C, SHERMAN W et al.: Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of Radiation Therapy Oncology Group Protocol 88-06. J. Clin. Oncol. (1996) 14:556-564.
34. RUBINSTEIN LJ, HERMAN MM, LONG TG, WILBUR JR: Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer (1975) 35:291-305.
35. POSNER JB: Neurologic complications of cancer. FA Davis Company, Philadelphia, PA, USA (1995) 282-310.
36. MALONEY DG, SMITH B, ROSE A: Rituximab: mechanism of action and resistance. Semin. Oncol. (2002) 29:2-9.
37. RAIZER JJ, DEANGELIS LM, ZELENETZ AE, LAUREN AE: Activity of rituximab in primary central nervous system lymphoma PCNSL. Proc. Am. Soc. Clin. Oncol. (2000) 19:166a.
38. RUHSTALLER TW, AMSLER U, CERNY T: Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma? Ann. Oncol. (2000) 11:374-375.
39. HARJUNPAA A, WIKLUND T, COLLAN J et al.: Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk. Lymphoma (2001) 42:731-738.
40. RUBENSTEIN JL, COMBS D, ROSENBERG J et al.: Rituximab therapy for CNS lymphoma: targeting the leptomeningeal compartment. Blood (2003) 101:466-468.
41. SCHULZ H, PELS H, SCHMIDT-WOLF I et al.: Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica (2004):89:753-754.
42. PELS H, SCHULZ H, MANZKE O et al.: Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J. Neurooncol. (2002) 59:213-216.
43. ANGELOV L, VOGELBAUM MA, BARNETT GH et al.: Primary central nervous system lymphoma: response to temozolomide therapy. Neuro-Oncol. (2003) 5:347.
44. QUINN J, REARDON D, RICH J et al.: Phase II treatment of adults with newly diagnosed, progressive, or recurrent primary central nervous system lymphoma with Temodar. Neuro-Oncol. (2003) 5:354.
45. RENI M, MASON W. ZAJA F et al.: Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur. J. Cancer (2004) 40:1682-1688.
46. WONG ET, TISHLER R, BARRON L, WU JK: Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer (2004) 101:139-145.
47. WONG E, BARRON L, BLOOM J, WU J: Durable responses from immunochemotherapy with rituximab and temozolomide in patients with central nervous system lymphomas. Cancer Biother. Radiopharm. (2004) 19:514.
48. ENTING RH, DEMOPOULOS A, DEANGELIS LM, ABREY LE: Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology (2004) 63:901-903.
49. DILLMAN RO: Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J. Clin. Oncol. (2002) 20:3545-3557.
50. 90Y ibritumomab tiuxetan (Zevalin). Semin. Oncol. (2003) 30:6-10.
51. KEATING MJ, FLINN I, JAIN V et al.: Therapeutic role of alemtuzumab (campath-1H) in patients who have failed fludarabine: results of a large international study. Blood (2002) 99:3554-3561.
52. ÖSTERBORG A, DYER MJS, BUNJES D et al.: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J. Clin. Oncol. (1997) 15:1567-1574.
53. RAI KR, FRETER CE, MERCIER RJ et al.: Aletuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J. Clin. Oncol. (2002) 20:3891-3897.
54. KHORANA A, BUNN P, MCLAUGHLIN P, VOSE J, STEWART C, CZUCZMAN MS: A phase II multicenter study of campath-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk. Lymphoma (2001) 41:77-87.
55. LUNDIN J, ÖSTERBORG A, BRITTINGER G et al.: Campath-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkn's lymphoma: a phase II multicenter study. J. Clin. Oncol. (1998) 16:3257-3263.
56. SATO S, MILLER AS, INAOKI M et al.: CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity (1996) 5:551-562.
57. ENGEL P, NOJIMA Y, ROTHSTEIN D et al.: The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes. J. Immunol. (1993) 150:4719-4732.
58. LEONARD JP, COLEMAN M, KETAS JC: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J. Clin. Oncol. (2003) 21:3051-3059.
59. LEONARD JF, COLEMAN M, KETAS JC et al.: Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin. Cancer Res. (2004) 10:5327-5334.
60. MILLER DH, KHAN OA, SHEREMATA WA et al.: A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. (2003) 348:15-23.
61. O'CONNOR PW, GOODMAN A, WILLMER-HULME AJ et al.: Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology (2004) 62:2038-2043.
62. TEROL MJ, LÓPEZ-GUILLERMO A, BOSCH F et al.: Expression of beta-integrin adhesion molecules in non-Hodgkin's lymphoma: correlation with clinical and evolutive features. J. Clin. Oncol. (1999) 17:1869-1875.